GMAB Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (17 birž. 2024 @ 23:00):
Our systems believe the stock currently is undervalued by 0.03% compare to its pairs and should correct upwards.

Stats
Šios dienos apimtis	353 639
Vidutinė apimtis	445 779
Rinkos kapitalizacija	16.80B
EPS	$20.29 ( Q1 \| 2024-05-02 )
Kita pelno data	( $0.280 ) 2024-08-01
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	21.48 (Sector) 42.63 (Industry) 24.32
ATR14	$0.0120 (0.05%)

AADI -3.55%

ABCL -5.26%

ABCM 0.04%

ABEO -1.31%

ABIO -1.53%

ABOS -5.30%

ABSI -14.32%

ABUS -2.55%

ABVX -0.22%

ACAD -0.47%

ACER -17.95%

ACET -2.22%

ACGN 1.29%

ACHL 0.23%

ACHV 1.63%

ACIU -4.23%

ACLX -1.21%

ACRV -5.10%

ACST 0.62%

ACXP -0.42%

ADAG -5.64%

ADAP -7.23%

ADGI 0.87%

ADIL -2.29%

ADMA -1.79%

ADPT 0.32%

ADTX -7.69%

ADVM -3.94%

ADXN -6.11%

AEON 11.51%

AEZS -5.44%

AFMD -5.07%

AGEN -7.50%

AGIO -3.45%

AGLE 6.66%

AGTC 0.00%

AIKI 0.85%

AIMDW 53.45%

AKBA -1.87%

AKRO -4.46%

AKTX -6.33%

AKUS 0.00%

ALBO 0.00%

ALDX -1.34%

ALEC -2.35%

ALGS -5.76%

ALKS 2.08%

ALLK 0.86%

ALLO -2.13%

ALLR -3.01%

ALNA 3.16%

ALNY -1.93%

ALPN 0.00%

ALPX 0.00%

ALRN -0.31%

ALT -3.11%

ALVR -4.43%

ALXN 0.00%

ALXO -8.32%

ALZN -12.01%

AMRN -2.58%

AMTI -3.13%

ANAB -1.64%

ANEB -5.58%

ANGN 0.00%

ANIX -0.38%

ANL 0.61%

ANNX -4.63%

ANPC -3.15%

APGE -5.23%

APGN 8.48%

APGNW 30.65%

APLM -4.73%

APLS -3.98%

APLT -4.36%

APM 1.33%

APOP 0.38%

APRE 2.44%

APTO -3.96%

APTX 3.17%

APVO -20.53%

ARAV -13.39%

ARCT -9.26%

ARDS 20.48%

ARDX -0.94%

ARGX -2.25%

ARNA 0.00%

ARPO -0.90%

ARQT -7.76%

ARTL -0.38%

ARTLW 9.80%

ARVN -2.84%

ARWR -2.86%

ASLN -12.17%

ASMB -1.49%

ASND -2.39%

ATAI -2.19%

ATHA 2.36%

ATHE -1.61%

ATHX -33.50%

ATNF 15.09%

ATOS -4.17%

ATRA -16.93%

ATXI -1.66%

ATXS -3.50%

AUPH -1.95%

AURA 0.96%

AUTL -4.22%

AVBP -1.02%

AVEO 0.00%

AVIR -2.22%

AVRO 2.10%

AVTE -93.30%

AVTX 4.08%

AVXL -1.06%

AXLA 0.00%

AXSM 3.22%

AYLA 0.00%

AZRX 2.07%

BBI 2.17%

BBIO -2.26%

BCAB -1.89%

BCDA -2.05%

BCDAW -33.33%

BCEL -1.32%

BCLI -8.47%

BCRX 1.13%

BCTX 4.96%

BCTXW 0.00%

BCYC -4.33%

BDRX 1.89%

BDTX -8.38%

BEAM -3.38%

BFRA -2.91%

BGNE -1.97%

BIOR -10.12%

BIVI 0.41%

BLCM -6.68%

BLI -5.88%

BLPH -0.79%

BLRX -3.79%

BLTE -0.72%

BLU 0.03%

BLUE -0.77%

BMEA -9.75%

BMRN 1.81%

BNOX 1.64%

BNTC 2.46%

BNTX -3.95%

BOLD -5.95%

BOLT -0.82%

BPMC -1.59%

BPTH 10.65%

BPTS -13.47%

BRNS -6.63%

BRTX 20.00%

BTAI -2.92%

BTTX -7.50%

BTX 0.05%

BVXV 0.74%

BXRX 7.39%

BYSI 6.06%

CABA -12.20%

CADL -0.96%

CALA 60.00%

CALC -1.62%

CALT 0.03%

CAPR -4.06%

CARA -27.26%

CARM -9.65%

CASI -8.04%

CATB -6.97%

CBAY 0.03%

CBIO -2.65%

CBLI -7.31%

CBUS 3.07%

CCCC -5.48%

CCXI 0.00%

CDAK 0.00%

CDIO -1.51%

CDIOW -23.08%

CDMO 5.72%

CDMOP 0.04%

CDT -6.11%

CDTTW -47.71%

CDTX -6.32%

CDXC -0.67%

CDXS -2.30%

CELC -2.79%

CELU -2.19%

CELUW -9.52%

CERC -1.68%

CERE -0.16%

CERO -7.87%

CEROW -44.78%

CFRX -27.95%

CGEM 0.74%

CGEN -5.31%

CGON -2.68%

CGTX 0.92%

CHMA -6.00%

CHRS -2.96%

CINC 0.00%

CING -1.09%

CINGW -48.24%

CKPT -4.25%

CLBS -16.75%

CLDX 0.69%

CLGN 1.19%

CLLS -4.89%

CLNN -2.48%

CLNNW -41.25%

CLRB -9.94%

CLSD -0.84%

CLSN -0.68%

CLVS 0.00%

CMMB -24.79%

CMND 1.83%

CMPI 0.00%

CMPX 5.41%

CMRA 0.40%

CMRAW 33.33%

CMRX 1.44%

CNCE 0.00%

CNSP 3.94%

CNST 0.00%

CNTA -6.39%

CNTB 3.13%

CNTX -1.02%

COCP -0.16%

COEPW -0.66%

COGT 4.45%

CORT -1.31%

COYA -6.11%

CPRX -0.40%

CRBP -11.76%

CRBU -2.23%

CRDF -1.11%

CRGX -4.78%

CRIS 1.11%

CRNX -1.37%

CRSP -2.79%

CRTX 2.63%

CRVO -1.89%

CRVS -5.39%

CSBR 1.19%

CTCX -8.04%

CTIC 0.06%

CTMX -0.72%

CTNM 0.00%

CTXR -1.50%

CUE -1.47%

CVAC -5.18%

CVKD 3.18%

CWBR -2.55%

CYAD -12.96%

CYCC -3.55%

CYCCP -1.79%

CYCN 6.00%

CYT -2.27%

CYTK -2.13%

CYTO 2.48%

DARE -3.31%

DAWN -4.60%

DBTX -0.81%

DBVT 1.01%

DFFN 10.28%

DICE 0.06%

DMAC -0.42%

DNLI -1.21%

DNTH -2.85%

DOMH 1.99%

DRMA 0.00%

DRMAW 0.00%

DRNA 0.00%

DRTS -1.32%

DRTSW 1.01%

DRUG 0.00%

DSGN 2.97%

DTIL -2.07%

DYAI -5.29%

EARS -1.77%

EDIT 0.20%

EDSA 1.04%

EFTR -3.13%

EFTRW -0.26%

EIGR 0.00%

ELAB 1.44%

ELDN -6.93%

ELEV -7.89%

ELOX -12.50%

ELTX -2.33%

ELVN -0.65%

ELYM -13.05%

ENGN -3.89%

ENGNW -7.06%

ENLV -3.47%

ENOB 1.79%

ENSC -0.55%

ENTA -6.00%

ENTO -2.80%

ENTX 0.00%

ENVB -4.64%

EPIX -8.75%

EPRX -0.19%

EPZM 0.00%

EQ 0.50%

EQRX -2.09%

EQRXW 0.00%

ERAS -7.83%

ERNA 2.60%

ERYP 1.30%

ESLA -6.38%

ESLAW -9.25%

ETNB 1.03%

ETON -5.90%

ETTX 0.00%

EVAX -19.54%

EVGN -2.14%

EVLO 50.00%

EWTX -0.80%

EXAI 1.19%

EXEL 0.18%

EYEG -0.43%

EYEN 1.57%

EYPT -3.94%

FATE -1.11%

FBIO 1.60%

FBIOP -1.05%

FBLG -5.34%

FBRX -7.46%

FDMT 0.72%

FENC 0.74%

FGEN -5.36%

FHTX 9.52%

FIXX 0.77%

FMTX 0.00%

FNCH -6.25%

FOLD -0.99%

FREQ 4.76%

FRLN 0.15%

FRTX -0.54%

FSTX 0.00%

FTRE 0.38%

FULC -6.04%

FUSN 0.00%

FWBI 4.59%

FWP 0.00%

GALT -4.58%

GANX 6.45%

GBIO 6.57%

GBT 0.01%

GDTC 2.16%

GERN -4.11%

GHRS 3.42%

GLMD -6.66%

GLPG 1.18%

GLSI 18.16%

GLTO -4.90%

GLUE -4.18%

GLYC -9.70%

GMAB -1.57%

GMDA 0.00%

GMTX 0.00%

GNCA -85.71%

GNFT 0.14%

GNLX 1.27%

GNPX 1.84%

GNTA -0.60%

GOSS 0.02%

GOVX -7.50%

GOVXW -24.72%

GPCR 0.85%

GRAY -10.80%

GRCL 0.05%

GRNA -0.03%

GRNAW 8.91%

GRPH -2.75%

GRTS -2.71%

GRTX -4.26%

GTHX -3.96%

GUTS -3.90%

GXGXW 41.67%

GYRE 4.44%

HALO 0.32%

HARP 0.09%

HCWB -9.73%

HEPA -6.36%

HGEN -84.62%

HILS 5.66%

HLVX 1.33%

HOOK -4.04%

HOTH -3.73%

HOWL 3.99%

HRMY 1.10%

HRTX -10.42%

HSTO 62.16%

HUMA -12.20%

HUMAW -5.97%

IBRX -2.18%

ICCC 2.84%

ICPT 0.21%

ICU 1.30%

ICUCW -10.39%

ICVX -0.91%

IDRA -23.04%

IDYA -1.44%

IFRX -3.21%

IGMS 0.41%

IKNA -0.57%

IKT 8.90%

IMAB -1.09%

IMCR -3.82%

IMGN 0.02%

IMGO 0.00%

IMMP -0.74%

IMMX -0.49%

IMNM -11.86%

IMNN -1.80%

IMPL -27.27%

IMRA 15.96%

IMRN -2.78%

IMRX 1.66%

IMTX -0.08%

IMTXW -2.70%

IMUX -4.20%

IMV 0.00%

IMVT 3.08%

INAB -8.26%

INBX -9.62%

INCY 0.93%

INDP 7.98%

INFI -52.38%

INKT -1.05%

INM -2.58%

INMB -2.47%

INO -1.65%

INSM 1.22%

INTS -5.63%

INVA 1.57%

INZY -2.95%

IOBT -6.11%

IONS 0.27%

IOVA -0.98%

IPA 0.48%

IPHA -10.64%

IPSC 0.64%

IRON -3.05%

ISEE 0.38%

ITOS -6.04%

ITRM -1.74%

IVA -10.10%

IVVD -6.96%

JAGX -6.67%

JANX -4.57%

JAZZ 1.43%

JNCE 0.00%

JSPR -2.80%

JSPRW 2.33%

JUNS 0.00%

JUNSW 0%

KA 4.11%

KALV -2.07%

KDNY 0.22%

KMPH -0.34%

KNSA -1.28%

KNTE -0.38%

KOD -4.27%

KPRX -21.08%

KPTI 1.69%

KRBP 4.17%

KRON -3.70%

KROS -9.68%

KRRO -16.54%

KRTX 0.03%

KRYS -0.04%

KTRA -2.35%

KTTA -2.85%

KTTAW 8.62%

KURA -0.62%

KYMR -4.42%

KYTX -17.21%

KZIA -1.29%

KZR -2.71%

LABP 0.57%

LBPH 1.67%

LBPS 0.00%

LBPSW 14.81%

LEGN -2.24%

LENZ -0.54%

LEXX -5.18%

LEXXW -9.42%

LGND 0.72%

LGNDV 0.00%

LGVN -24.76%

LIAN 0.00%

LIFE 2.70%

LIPO -1.23%

LIXT 0.40%

LIXTW 27.74%

LJPC -0.32%

LMNL 0.12%

LOGC 2.76%

LPCN 12.64%

LPTX -1.90%

LQDA 3.01%

LRMR -14.91%

LSTA -4.97%

LTRN -8.57%

LUMO -2.95%

LVTX -9.52%

LXEO -6.50%

LXRX -5.49%

LYEL -8.05%

LYRA -8.37%

MACK 0.00%

MBIO 476.92%

MBRX -4.83%

MCRB -5.28%

MDGL -0.31%

MDNA -13.16%

MDWD 1.00%

MDXG 0.59%

MEIP 1.41%

MESO -0.55%

MGNX -4.03%

MGTA -7.74%

MGTX -2.23%

MGX -24.14%

MIRM 27.31%

MIRO 0.59%

MIST -1.42%

MITO 0.00%

MLEC -4.55%

MLECW 9.20%

MLND -5.36%

MLTX -2.99%

MLYS -3.02%

MNKD -1.04%

MNMD -3.36%

MNOV 0.00%

MNPR -8.51%

MOLN 8.81%

MOR 0.88%

MORF -1.25%

MREO 0.00%

MRKR 16.59%

MRNA -1.52%

MRNS -1.02%

MRSN -1.45%

MRTX -0.17%

MRUS -1.38%

MRVI -3.99%

MTCR -1.29%

MTEM 1.54%

MTP -18.50%

MURA 2.17%

MYMD 4.19%

NAMS -7.03%

NAMSW -7.61%

NAUT 0.00%

NBRV 0.71%

NBSE -1.56%

NBTX 4.77%

NCNA -1.64%

NERV 8.96%

NEXI 0.00%

NGM -1.28%

NGNE -6.08%

NKGN -4.44%

NKGNW 39.76%

NKTR 0.00%

NKTX -5.66%

NLSP 30.09%

NLSPW -16.67%

NMRA -4.09%

NMTR -42.97%

NOVN -24.84%

NRBO 0.45%

NRIX 0.72%

NRSN -3.82%

NRSNW 6.50%

NRXP 0.99%

NRXPW -15.65%

NRXS -6.06%

NTBL 13.82%

NTEC -12.45%

NTHI 0%

NTLA 0.08%

NTRBW -6.25%

NUVL -0.77%

NVAX -2.43%

NVCT 1.18%

NVIV -34.28%

NXTC -10.63%

NYMX -0.05%

OABI 0.95%

OABIW 13.46%

OBIO 0.88%

OBSV 0.00%

OCEA 10.64%

OCGN -5.63%

OCS -1.09%

OCUL -4.35%

OCUP 1.82%

ODT -4.27%

OKYO 0.00%

OLMA -3.96%

OMER -0.49%

OMGA -8.37%

ONCO 12.54%

ONCR -3.08%

ONCS 31.87%

ONCT -0.12%

ONCY -0.98%

ONTX -0.47%

ONVO 0.62%

OPNT 0.00%

OPT -5.51%

ORGS -1.72%

ORIC -0.67%

ORMP -0.44%

ORPH 0.00%

ORTX 0.30%

OSMT -1.77%

OTIC -92.64%

OTLK -1.43%

OVID -76.00%

OYST 0.00%

PALI 0.86%

PASG -3.81%

PBLA 9.76%

PBM -0.02%

PBYI 2.89%

PCSA 5.71%

PCVX -1.45%

PDSB -4.13%

PEPG 0.70%

PGEN 0.00%

PHAR 2.17%

PHAS 0.00%

PHAT 3.08%

PHIO 4.14%

PHIOW 36.47%

PHVS -0.53%

PHXM -5.20%

PIRS -5.64%

PKBO 0.00%

PKBOW 999 900.00%

PLRX -5.08%

PLUR 0.00%

PMN -5.59%

PMVP -1.20%

PNT 0.16%

PPBT -11.48%

PRAX -6.21%

PRDS 0.93%

PRLD 0.77%

PROG -3.47%

PROK 6.96%

PRQR -3.41%

PRTA -0.20%

PRTC -0.72%

PRTG -1.96%

PRTK 1.83%

PRVB 0.00%

PSTI -2.91%

PSTV 0.00%

PSTX 1.81%

PTCT -1.14%

PTE -0.82%

PTGX -2.76%

PTIXW 2.50%

PULM 3.72%

PXMD -1.92%

PYPD -0.36%

PYXS -3.43%

QLGN -11.72%

QNCX 0.00%

QNRX -10.97%

QSI -2.92%

QSIAW 0.00%

QTTB 3.82%

QURE -4.09%

RAIN -1.63%

RANI -5.46%

RAPT -0.30%

RARE 1.92%

RCKT -3.02%

REGN 0.85%

RENB -3.05%

REPL -6.63%

RETA 0.02%

REUN -0.89%

REVB 1.36%

REVBU 3.46%

REVBW 25.20%

RGLS -1.66%

RGNX -6.20%

RIGL -2.79%

RLAY -3.01%

RLMD -0.33%

RLYB -6.15%

RNA -0.10%

RNAC -14.55%

RNAZ -5.83%

RNXT 14.41%

ROIV 0.28%

ROIVW 4.56%

RPHM -0.60%

RPRX -1.15%

RPTX 0.00%

RUBY 2.70%

RVLP -32.05%

RVMD -3.94%

RVMDW -23.93%

RVNC -0.71%

RVPH -0.68%

RVPHW 11.54%

RXDX 0.09%

RXRX 1.19%

RYTM -3.76%

RYZB 0.02%

RZLT -2.53%

SABS 3.17%

SABSW -32.14%

SAGE -6.08%

SANA -1.32%

SAVA 0.81%

SAVAW 0.00%

SBBP 1.52%

SBTX 1.03%

SCNI 60.46%

SCPH -1.69%

SCPS 0.00%

SEEL -4.62%

SEER -3.37%

SELB -8.00%

SESN 7.29%

SGEN -0.07%

SGMO -17.30%

SGMT 1.93%

SGTX -2.56%

SIOX 22.63%

SLDB -5.44%

SLGL -2.22%

SLN -1.55%

SLNO 0.19%

SLRX 2.89%

SLS -16.67%

SMMT -5.84%

SNDX -1.14%

SNGX -5.91%

SNPX -3.97%

SONN -4.75%

SPPI -0.49%

SPRB 0.49%

SPRC -3.16%

SPRO -5.88%

SRNE 20.00%

SRPT -4.89%

SRRA 0.00%

SRRK -7.09%

SRZN -1.70%

STAB 0.00%

STOK -4.00%

STRO -7.51%

STSA 0.00%

STTK -19.55%

SURF -0.93%

SVRA -5.15%

SWTX -4.88%

SYBX -0.63%

SYRS -4.83%

TALS -0.73%

TARA -0.78%

TARS -6.91%

TBPH -0.59%

TCBP -8.64%

TCDA 0.00%

TCON 6.35%

TCRR 0.00%

TCRT 1.05%

TCRX -11.43%

TECH -1.40%

TENX -3.43%

TERN -2.93%

TFFP 0.52%

TGTX 0.12%

THRX 0.12%

TIL -2.06%

TLC 0.00%

TLSA 5.78%

TNGX 5.04%

TNXP -2.61%

TNYA -1.79%

TPST 0.34%

TRDA -3.61%

TRVI 2.08%

TRVN -1.88%

TSHA 1.51%

TSVT 3.29%

TTNP 1.45%

TVTX 2.23%

TYRA -8.69%

UBX -4.17%

UNCY 0.22%

URGN -4.79%

UTHR 3.12%

VACC 11.36%

VALN -1.55%

VAXX -0.11%

VBIV -3.61%

VBLT -8.77%

VCEL -1.37%

VCNX -3.70%

VCYT 1.96%

VERA -0.83%

VERU 2.29%

VERV -2.77%

VIGL -2.08%

VINC -4.90%

VIR -5.85%

VIRI 4.95%

VIRX -3.62%

VKTX 0.00%

VLON -13.04%

VNDA 1.76%

VOR 1.74%

VRCA 0.49%

VRDN -1.93%

VRNA 10.04%

VRPX 10.77%

VRTX -1.46%

VSTM 0.00%

VTGN -2.84%

VTVT -0.10%

VTYX -4.51%

VXRT -8.25%

VYGR -2.94%

VYNE 2.16%

VYNT 7.78%

WINT 7.98%

WVE -3.85%

XBIO 6.75%

XBIT -0.33%

XCUR -3.10%

XENE -1.75%

XERS -0.91%

XFOR -2.75%

XLO -6.86%

XLRN 0.00%

XNCR -5.15%

XOMA -4.31%

XOMAO 0.68%

XOMAP -0.14%

XRTX 1.96%

YMAB -1.34%

ZGNX 0.00%

ZIOP -0.88%

ZLAB 1.55%

ZNTL -5.09%

ZSAN 0.00%

Koreliacija (AI algo v.1.1b): Undervalued: 0.03% $25.79 paired level. (Algoritmas realiuoju laiku stebi didžiausią koreliaciją turinčių akcijų pokyčius ir suteikia momentinę informaciją)

Tūris Koreliacija

Ilgas: 0.05 (neutral)

Trumpas: 0.23 (neutral)

Signal:(42.538) Neutral

Genmab A/S Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Genmab A/S Koreliacija - Valiuta/Žaliavos

-0.11
( neutral )

-0.07
( neutral )

0.00
( neutral )

-0.09
( neutral )

0.00
( neutral )

0.36
( neutral )

Genmab A/S Finansinės ataskaitos

Annual	2023
Pajamos:	$16.47B
Bruto pelnas:	$15.92B (96.64 %)
EPS:	$66.64

FY	2023
Pajamos:	$16.47B
Bruto pelnas:	$15.92B (96.64 %)
EPS:	$66.64

FY	2022
Pajamos:	$14.60B
Bruto pelnas:	$14.60B (100.00 %)
EPS:	$83.38

FY	2021
Pajamos:	$8.48B
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$4.60

Financial Reports:

No articles found.

Genmab A/S Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.